Heron Therapeutics | HRTX - Sales Revenues

Stock Price
1.06
Daily Change
-0.07 -6.19%
Monthly
-12.40%
Yearly
-55.83%
Q1 Forecast
1.15

Heron Therapeutics reported $32.81M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
ALKERMES USD 384.5M 9.7M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.67M 23.07M Sep/2025
ANI Pharmaceuticals USD 247.06M 19.25M Dec/2025
Anika Therapeutics USD 26.17M 12.58M Mar/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Eisai JPY 219.94B 22.58B Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Insmed USD 263.8M 121.8M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Merck USD 16.4B 880M Dec/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Surmodics USD 29.92M 96.16M Dec/2024
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Veracyte USD 140.6M 8.7M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025